Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Region Örebro County
With
UBITECH
ATOS
Siemens Corporation, Corporate Technology
Intrasoft
University of Patras
FORTH - Foundation for Research and Technology Hellas
Sphynx Technology Solutions AG
University of Novi Sad
DFKI - German Research Center for Artificial Intelligence
CareAcross
National and Kapodistrian University of Athens
Fundacio Clinic Barcelona
Arthur's Legal
Fundacion iSYS
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient selection process varies among the different study sites. Three Hospitals (Sismanogleio General Hospital Athens (SGHA), Örebro University Hospital (ÖUH), Uppsala University Hospital (UUH)) will include patients with newly diagnosed breast- (ÖUH, UUH) or prostate cancer (SGHA, ÖUH) who are eligible for curative treatment with surgery (breast cancer in ÖUH and UUH; prostate cancer in NKUA) or radiotherapy (prostate cancer; ÖUH).
One Hospital (Barcelona) will include breast cancer survivors (at least 12 months after surgery or chemotherapy) with follow-up through the Hospital.
Finally, CareAcross will include patients with breast- or prostate cancer through its online platform for patients seeking for the CareAcross services.
breast cancer diagnosis
no clinical evidence of metastatic disease
able for curative treatment with surgery with or without oncological treatment.
prior early breast cancer who are at follow-up with at least 12 months after surgery or chemotherapy (whichever occurred last).
breast cancer diagnosis (as per self-reported) irrespective of stage and treatment.
proostate cancer diagnosis
no clinical evidence of metastatic disease
able for curative treatment with surgery with or without oncological treatment (SGHA) or radiotherapy (with or without prior surgery) irrespectively the type of radiotherapy (external radiotherapy, brachytherapy, or combination).
prostate cancer diagnosis (as per self-reported) irrespective of stage and treatment.
You may not be if
inability to give informed consent
inability / no access to smartphones, applications or internet services
patients with known medical history of allergy to the wearable material.
Clareo Health | Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project
